Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,284,664 papers from all fields of science
Search
Sign In
Create Free Account
Plerixafor
Known as:
1,1'-[1,4-Phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
, Bis(Tetraazacyclotetradecane) Derivative
A drug used before autologous stem cell transplantation in patients with non-Hodgkin lymphoma or multiple myeloma. Plerixafor is given together with…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
1.2 ML Plerixafor 20 MG/ML Injection [Mozobil]
CXCR4 protein, human
Narrower (3)
AMD3100
JM 3100
Mozobil
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar HGB-204 Study
J. Rasko
,
A. Thompson
,
+13 authors
M. Walters
Blood
2018
Corpus ID: 81357013
Background Advances in red blood cell (RBC) transfusion and chelation have improved the prognosis of patients with transfusion…
Expand
2017
2017
Results from the Hgb-207 (Northstar-2) Trial: A Phase 3 Study to Evaluate Safety and Efficacy of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in Patients with Non-β0/β0…
M. Walters
,
S. Hongeng
,
+10 authors
A. Thompson
2017
Corpus ID: 199608952
Background Gene therapy with LentiGlobin Drug Product (DP), which contains autologous CD34+ hematopoietic stem cells transduced…
Expand
2016
2016
Efficacy and Cost Analysis of a Plerixafor Protocol for Peripheral Blood Stem-Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma
J. Comeau
,
Pharmd
,
Bcop
2016
Corpus ID: 78982266
Autologous stem-cell transplantation (ASCT) extends overall survival for patients with multiple myeloma1 and is a potentially…
Expand
2015
2015
Diabetes: SDF-1 dysregulation mediates diabetic stem cell mobilopathy
D. Holmes
Nature Reviews Endocrinology
2015
Corpus ID: 32887943
2014
2014
syndrome with the CXCR4 antagonist plerixafor A phase 1 clinical trial of long-term, low-dose treatment of WHIM
P. Stratton
,
E. Cowen
,
+20 authors
Jean Ulrick
2014
Corpus ID: 162863699
online February 12, 2014doi:10.1182/blood-2013-09-527226 originally published2014€123: 2308-2316€€Pamela Stratton, Edward W…
Expand
Review
2012
Review
2012
Mobilizacja krwiotwórczych komórek macierzystych — wczoraj i dziś
Grzegorz W. Basak
,
W. Jędrzejczak
2012
Corpus ID: 78126336
The method of hematopoietic stem cells (HSC) mobilization to peripheral blood enabled theirefficient collection from peripheral…
Expand
2011
2011
AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest
S. Leotta
,
M. Poidomani
,
E. Mauro
,
A. Spadaro
,
E. Marturano
,
G. Milone
Bone Marrow Transplantation
2011
Corpus ID: 33950241
AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest
2010
2010
Efficacy and safety of hematopoietic stem cell (HSC) remobilization with plerixafor plus G-CSF in patients with non-hematologic malignancies.
M. Horwitz
,
J. Schriber
,
+4 authors
P. Holman
2010
Corpus ID: 79435821
e15072 Background: Although high dose chemotherapy followed by autologous HSC transplantation is a potentially curative procedure…
Expand
2010
2010
CXCR4 inhibitor plerixafor and G-CSF allow for an effective peripheral blood stem cell collection in patients who failed previous mobilization attempt
G. Basak
,
E. Urbanowska
,
+14 authors
W. Wiktor-Jedrzejczak
2010
Corpus ID: 54672311
Background: Plerixafor is a CXCR4 receptor inhibitor, which was recently introduced for stem cell mobilization in myeloma and…
Expand
2009
2009
Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards!
M. Mohty
Leukemia
2009
Corpus ID: 20643018
Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards!